[New insights into the pathogenesis and molecular understanding of cutaneous T-cell lymphomas].

Autor: Stadler R; Universitätsklinik für Dermatologie, Johannes Wesling Klinikum Minden, UK RUB, Hans-Nolte-Str. 1, 32429, Minden, Deutschland. rudolf.stadler@ruhr-uni-bochum.de., Hain C; Zentrum für Biotechnologie (CeBiTec), Universität Bielefeld, Bielefeld, Deutschland.
Jazyk: němčina
Zdroj: Dermatologie (Heidelberg, Germany) [Dermatologie (Heidelb)] 2022 Oct; Vol. 73 (10), pp. 765-771. Date of Electronic Publication: 2022 Aug 12.
DOI: 10.1007/s00105-022-05047-9
Abstrakt: The pathogenesis of cutaneous T‑cell lymphomas (CTCL) is still an enigma. Therefore, extensive translational research efforts have been undertaken in recent years to gain further clinical and molecular insights. There is increasing evidence that the different clinical appearance of the CTCL subtypes derives from the assumption that they develop from different skin subpopulations of T cells. Detection and quantification of the malignant T‑cell clones is crucial for the diagnosis and prognosis of CTCL. Numerous recurrent mutant cellular signalling pathways have been found in recent years. This includes the JAK-STAT, NFκB, T‑cell receptor and MAP kinase signalling pathways, as well as cell cycle control and epigenetics. The most recent analyses imply a tumour evolution model with initial copy number variation, like amplification or deletions of specific DNA fragments (CNVs) and only subsequent later single nucleotide variations (SNVs). The crucial question, however, is which CNVs are sufficient to initiate general tumourigenesis? The challenge is to identify possible driver genes. Increasing molecular understanding in CTCL will include new breakthrough therapeutic options in the near future.
(© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)
Databáze: MEDLINE
Externí odkaz: